Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/25/2851654/30541/en/ProLynx-announces-initiation-of-the-Phase-II-Topology-clinical-trial-of-its-DNA-damaging-agent-PLX038-in-triple-negative-breast-cancer-at-the-Institut-Curie.html
https://www.globenewswire.com//news-release/2024/02/05/2823569/30541/en/ProLynx-announces-initiation-of-Phase-I-II-clinical-trial-of-its-DNA-damaging-agent-PLX038-in-patients-with-rare-CNS-tumors-at-the-National-Cancer-Institute-NCI.html
https://www.globenewswire.com//news-release/2024/01/24/2815405/30541/en/ProLynx-announces-a-publication-proposing-that-a-long-acting-prodrug-of-SN-38-could-be-effective-in-treating-Sacituzumab-Govitecan-Resistant-Tumors.html
https://www.globenewswire.com/news-release/2022/10/07/2530299/30541/en/ProLynx-announces-initiation-of-Phase-II-clinical-trial-of-its-DNA-damaging-agent-PLX038-in-patients-with-platinum-resistant-Ovarian-Cancer-at-the-Mayo-Clinic.html
https://www.globenewswire.com/news-release/2022/09/20/2518987/30541/en/ProLynx-appoints-Richard-King-as-Chief-Executive-Officer-and-Chris-Ehrlich-as-Board-Director.html
http://www.globenewswire.com/news-release/2020/07/07/2058644/0/en/ProLynx-announces-SBIR-grant-award-to-develop-long-acting-parathyroid-hormone-for-hypo-parathyroidism.html#:~:text=The%20grant%20was%20conferred%20for,using%20its%20hydrogel%20microsphere%20carriers.